Published in Clin Oncol (R Coll Radiol) on May 07, 2013
Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer (1994) 3.25
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol (2013) 2.38
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol (2004) 1.73
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol (1996) 1.61
Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology (1995) 1.50
Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer (2005) 1.49
The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol (2000) 1.41
Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res (2000) 1.41
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol (2014) 1.39
In situ replacement of the aorta in a contaminated field with the infrarenal inferior vena cava. J Vasc Surg (1999) 1.39
Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem (1997) 1.38
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res (2000) 1.35
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol (2005) 1.21
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol (2000) 1.17
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol (2009) 1.16
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology (2000) 1.13
Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther (2001) 1.12
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst (2000) 1.10
A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res (1997) 1.08
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res (1993) 1.05
Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res (2001) 1.05
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res (2000) 1.04
Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res (1999) 1.03
Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia (2001) 1.02
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol (2010) 0.99
GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene (2012) 0.98
Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl (1992) 0.98
Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res (2001) 0.95
Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Br J Urol (1998) 0.95
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2000) 0.94
Inflammatory pseudotumor of the urinary bladder: a report of five cases and review of the literature. Can J Urol (2001) 0.94
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res (2001) 0.93
Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int (2003) 0.92
Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ (2011) 0.92
International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. Br J Cancer (2012) 0.90
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol (2009) 0.89
Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surv (1991) 0.88
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Br J Cancer (2012) 0.88
Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer (2001) 0.87
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol (2012) 0.86
Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol (2001) 0.85
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Ann Oncol (2004) 0.83
Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate (2000) 0.83
Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer (2000) 0.83
The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res (2000) 0.82
Early experience with high-intensity focused ultrasound for the treatment of benign prostatic hypertrophy. Br J Urol (1997) 0.81
Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol (2008) 0.81
Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration. Urology (1996) 0.81
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer (2009) 0.80
The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice. Prostate Cancer Prostatic Dis (2013) 0.80
Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res (1999) 0.79
Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol (2010) 0.79
[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer]. Urologe A (2008) 0.78
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. Invest New Drugs (2013) 0.78
Transurethral electrovaporization of the prostate versus transurethral prostatic resection: a comparison of postoperative hemorrhage. Urology (1998) 0.77
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs (2015) 0.77
Multimodal approaches to high-risk prostate cancer. Curr Oncol (2010) 0.76
Therapeutic strategies for localized prostate cancer I: surgery, ultrasound, adjuvant and neoadjuvant therapy. Rev Urol (2000) 0.75
Advanced prostate cancer: an update. Rev Urol (2000) 0.75
The best local therapy for unfavorable risk prostate cancer: the role of surgery. Minerva Urol Nefrol (2006) 0.75
Re: Editorial comment. J Urol (1997) 0.75
[In vitro and in vivo models developed from human prostatic cancer]. Prog Urol (1997) 0.75
[Stress proteins in prostate cancer. Challenge and promise]. Urologe A (2007) 0.75
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol (2016) 0.75